Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2006-5-2
pubmed:abstractText
The sympathetic nerve activity plays an important role on the renal function through the vasoactive system and the renin-angiotensin system. Although interest in the renal protective effects of anti-sympathetic agents has been increased, there are not enough data to clarify this efficiency. Therefore, we investigated the effects of L/N-type calcium channel antagonist, cilnidipine on progressive renal injury in Dahl salt-sensitive (Dahl S) rats. Male Dahl S rats (6 weeks of age) were fed a high salt (4% NaCl) diet. They were divided into groups with similar blood pressure at 12 weeks of age and they received vehicle (n=7) or cilnidipine (30 mg/kg/d as food admix, n=9) for 8 weeks. Cilnidipine treatment suppressed the increase in systolic blood pressure. Although urinary protein excretion was not influenced, cilnidipine inhibited the increase in blood urea nitrogen and decrease in creatinine clearance. Histological investigation revealed that progression of glomerular sclerosis was inhibited in cilnidipine treatment group. Of notes, cilnidipine reduced plasma norepinephrine level and plasma rennin activity compared with vehicle-treated Dahl S rats. These data indicated that cilnidipine has suppressive effects against progressive renal injury in Dahl S rats. This effect is not only explained by the L-type calcium channel blocking action that lowered blood pressure, but also partially explained by the N-type calcium channel blocking action that lead to suppression of the sympathetic nerve activity and renin-angiotensin system.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0918-6158
pubmed:author
pubmed:issnType
Print
pubmed:volume
29
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
933-7
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:16651722-Angiotensin II, pubmed-meshheading:16651722-Animals, pubmed-meshheading:16651722-Blood Pressure, pubmed-meshheading:16651722-Calcium Channel Blockers, pubmed-meshheading:16651722-Calcium Channels, L-Type, pubmed-meshheading:16651722-Calcium Channels, N-Type, pubmed-meshheading:16651722-Dihydropyridines, pubmed-meshheading:16651722-Disease Progression, pubmed-meshheading:16651722-Hemodynamics, pubmed-meshheading:16651722-Hypertension, pubmed-meshheading:16651722-Kidney, pubmed-meshheading:16651722-Kidney Cortex, pubmed-meshheading:16651722-Kidney Failure, Chronic, pubmed-meshheading:16651722-Kidney Function Tests, pubmed-meshheading:16651722-Male, pubmed-meshheading:16651722-Norepinephrine, pubmed-meshheading:16651722-Rats, pubmed-meshheading:16651722-Rats, Inbred Dahl, pubmed-meshheading:16651722-Renin, pubmed-meshheading:16651722-von Willebrand Factor
pubmed:year
2006
pubmed:articleTitle
Effects of L/N-type calcium channel antagonist, cilnidipine on progressive renal injuries in Dahl salt-sensitive rats.
pubmed:affiliation
Pharmaceutical Research Laboratories, Ajinomoto Co., Inc., Kawasaki, Kanagawa, Japan. tomoyuki_konda@ajinimoto.com
pubmed:publicationType
Journal Article